484 related articles for article (PubMed ID: 28770276)
1. A comparative study of QT prolongation with serotonin reuptake inhibitors.
Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
[TBL] [Abstract][Full Text] [Related]
2. Hypertension induced by serotonin reuptake inhibitors: analysis of two pharmacovigilance databases.
Humbert X; Fedrizzi S; Chrétien B; Sassier M; Bagheri H; Combret S; Drici MD; Le Bas F; Puddu PE; Alexandre J
Fundam Clin Pharmacol; 2019 Jun; 33(3):296-302. PubMed ID: 30489655
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the risk of QT prolongation among SSRIs.
Funk KA; Bostwick JR
Ann Pharmacother; 2013 Oct; 47(10):1330-41. PubMed ID: 24259697
[TBL] [Abstract][Full Text] [Related]
4. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
Assimon MM; Brookhart MA; Flythe JE
J Am Soc Nephrol; 2019 Apr; 30(4):611-623. PubMed ID: 30885935
[TBL] [Abstract][Full Text] [Related]
5. Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.
Trenque T; Maura G; Herlem E; Vallet C; Sole E; Auriche P; Drame M
Drug Saf; 2013 Jul; 36(7):515-9. PubMed ID: 23728950
[TBL] [Abstract][Full Text] [Related]
6. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
Chastang A; Renet S; Corny J; Beaussier H; Petre A; Lillo-Lelouet A; Phan Thi TT; Bézie Y
Int J Clin Pharm; 2019 Feb; 41(1):42-48. PubMed ID: 30610545
[TBL] [Abstract][Full Text] [Related]
7. A question about the potential cardiac toxicity of escitalopram.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2012 Apr; 50(4):17-20. PubMed ID: 22421011
[TBL] [Abstract][Full Text] [Related]
8. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.
Revet A; Montastruc F; Roussin A; Raynaud JP; Lapeyre-Mestre M; Nguyen TTH
BMC Psychiatry; 2020 Jun; 20(1):308. PubMed ID: 32546134
[TBL] [Abstract][Full Text] [Related]
9. High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.
Ray WA; Chung CP; Murray KT; Hall K; Stein CM
J Clin Psychiatry; 2017 Feb; 78(2):190-195. PubMed ID: 27736049
[TBL] [Abstract][Full Text] [Related]
10. The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Hussaarts KGAM; Berger FA; Binkhorst L; Oomen-de Hoop E; van Leeuwen RWF; van Alphen RJ; Mathijssen-van Stein D; de Groot NMS; Mathijssen RHJ; van Gelder T
Pharm Res; 2019 Dec; 37(1):7. PubMed ID: 31845095
[TBL] [Abstract][Full Text] [Related]
11. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
Crépeau-Gendron G; Brown HK; Shorey C; Madan R; Szabuniewicz C; Koh S; Veinish S; Mah L
J Affect Disord; 2019 May; 250():341-345. PubMed ID: 30877856
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
Sullivan PW; Valuck R; Saseen J; MacFall HM
CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
[TBL] [Abstract][Full Text] [Related]
13. Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database.
Trenque T; Herlem E; Auriche P; Dramé M
Drug Saf; 2011 Dec; 34(12):1161-6. PubMed ID: 22077504
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.
Beach SR; Kostis WJ; Celano CM; Januzzi JL; Ruskin JN; Noseworthy PA; Huffman JC
J Clin Psychiatry; 2014 May; 75(5):e441-9. PubMed ID: 24922496
[TBL] [Abstract][Full Text] [Related]
15. The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.
Assimon MM; Pun PH; Al-Khatib SM; Brookhart MA; Gaynes BN; Winkelmayer WC; Flythe JE
Nephrol Dial Transplant; 2022 Oct; 37(11):2241-2252. PubMed ID: 35793567
[TBL] [Abstract][Full Text] [Related]
16. [Citalopram and QT prolongation].
Alušík Š; Paluch Z
Vnitr Lek; 2018; 63(12):952-956. PubMed ID: 29334745
[TBL] [Abstract][Full Text] [Related]
17. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Sanchez C; Reines EH; Montgomery SA
Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
[TBL] [Abstract][Full Text] [Related]
18. [The transfer of selective serotonin reuptake inhibitors to human milk].
Nordeng H; Bergsholm YK; Bøhler E; Spigset O
Tidsskr Nor Laegeforen; 2001 Jan; 121(2):199-203. PubMed ID: 11475200
[TBL] [Abstract][Full Text] [Related]
19. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.
Maljuric NM; Noordam R; Aarts N; Niemeijer MN; van den Berg ME; Hofman A; Kors JA; Stricker BH; Visser LE
Br J Clin Pharmacol; 2015 Oct; 80(4):698-705. PubMed ID: 25966843
[TBL] [Abstract][Full Text] [Related]
20. [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Vinnikova MA; Severtsev VV; Komarov SD; Vdovin AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(12):57-62. PubMed ID: 35041313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
